NCT03322540 2025-08-22Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)Incyte CorporationPhase 2 Completed154 enrolled 14 charts
NCT03322566 2022-01-24A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)Incyte CorporationPhase 2 Completed233 enrolled 16 charts
NCT01685255 2019-03-11A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line ChemotherapyIncyte CorporationPhase 2 Terminated83 enrolled